12/23
04:05 pm
solv
Solventum Completes Acquisition of Acera Surgical
Low
Report
Solventum Completes Acquisition of Acera Surgical
12/17
04:05 pm
solv
Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
Low
Report
Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
12/17
08:04 am
solv
Solventum (NYSE:SOLV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Solventum (NYSE:SOLV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/16
04:05 pm
solv
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
Low
Report
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
12/13
01:10 am
solv
Low
Report
12/3
07:57 am
solv
Solventum (NYSE:SOLV) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Solventum (NYSE:SOLV) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
12/2
07:10 am
solv
Solventum (NYSE:SOLV) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating.
Low
Report
Solventum (NYSE:SOLV) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating.
12/2
07:08 am
solv
Solventum (NYSE:SOLV) was given a new $100.00 price target on by analysts at BTIG Research. They now have a "reduce" rating on the stock.
Low
Report
Solventum (NYSE:SOLV) was given a new $100.00 price target on by analysts at BTIG Research. They now have a "reduce" rating on the stock.
12/1
03:41 am
solv
Medium
Report
11/25
04:05 pm
solv
Solventum to Participate in the 2025 Piper Sandler Healthcare Conference
Low
Report
Solventum to Participate in the 2025 Piper Sandler Healthcare Conference
11/23
02:11 am
solv
Low
Report
11/21
12:06 pm
solv
Solventum (NYSE:SOLV) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Solventum (NYSE:SOLV) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
11/20
09:00 am
solv
Solventum Announces Agreement to Acquire Acera Surgical
Low
Report
Solventum Announces Agreement to Acquire Acera Surgical
11/20
09:00 am
solv
Solventum Announces $1 Billion Share Repurchase Program
Low
Report
Solventum Announces $1 Billion Share Repurchase Program
11/15
01:42 am
solv
Low
Report
11/10
03:21 pm
solv
Solventum (NYSE:SOLV) had its price target raised by analysts at UBS Group AG from $77.00 to $79.00. They now have a "neutral" rating on the stock.
Low
Report
Solventum (NYSE:SOLV) had its price target raised by analysts at UBS Group AG from $77.00 to $79.00. They now have a "neutral" rating on the stock.
11/7
08:07 am
solv
Solventum (NYSE:SOLV) had its price target raised by analysts at Piper Sandler from $94.00 to $98.00. They now have an "overweight" rating on the stock.
Medium
Report
Solventum (NYSE:SOLV) had its price target raised by analysts at Piper Sandler from $94.00 to $98.00. They now have an "overweight" rating on the stock.
11/6
04:05 pm
solv
Solventum Reports Third Quarter 2025 Financial Results
Medium
Report
Solventum Reports Third Quarter 2025 Financial Results
11/3
04:05 pm
solv
Solventum to Participate in the 2025 Stifel Healthcare Conference
Low
Report
Solventum to Participate in the 2025 Stifel Healthcare Conference
10/30
12:31 pm
solv
Solventum (NYSE:SOLV) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Solventum (NYSE:SOLV) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
10/21
05:00 pm
solv
Solventum Appoints Heather Knight as Chief Commercial Officer
Low
Report
Solventum Appoints Heather Knight as Chief Commercial Officer
10/16
04:05 pm
solv
Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025
Low
Report
Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025
10/3
06:38 am
solv
Solventum (NYSE:SOLV) was upgraded by analysts at UBS Group AG to a "hold" rating.
Low
Report
Solventum (NYSE:SOLV) was upgraded by analysts at UBS Group AG to a "hold" rating.
10/1
07:04 am
solv
Solventum (NYSE:SOLV) was given a new $77.00 price target on by analysts at UBS Group AG.
Low
Report
Solventum (NYSE:SOLV) was given a new $77.00 price target on by analysts at UBS Group AG.